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Abstract Although colonoscopic surveillance is recom-
mended both for individuals with known hereditary col-
orectal cancer (HCRC) syndromes and those with a more
moderate familial colorectal cancer (FCRC) history, the
evidence for the benefits of surveillance is limited and
surveillance practices vary. This study evaluates the pre-
ventive effect for individuals with a family history of CRC
of decentralized colonoscopic surveillance with the guid-
ance of a cancer prevention clinic. We performed a pop-
ulation based prospective study of 261 patients with HCRC
or FCRC, recorded in the colonoscopic surveillance reg-
istry at the Cancer genetics clinic, University Hospital of
Umea˚, Sweden. Colonoscopic surveillance was conducted
every second (HCRC) or fifth (FCRC) year at local hos-
pitals in Northern Sweden. Main outcome measures were
findings of high-risk adenomas (HRA) or CRC, and patient
compliance to surveillance. Estimations of the expected
numbers of CRC without surveillance were made. During a
total of 1256 person years of follow-up, one case of CRC
was found. The expected numbers of cancers in the absence
of surveillance was between 9.5 and 10.5, resulting in a
standardized incidence ratio, observed versus expected
cases of CRC, between 0.10 (CI 95 % 0.0012–0.5299) and
0.11 (CI 95 % 0.0014–0.5857). No CRC mortality was
reported, but three patients needed surgical intervention.
HRA were found in 5.9 % (14/237) of the initial and in
3.4 % (12/356) of the follow-up colonoscopies. Patient
compliance to the surveillance program was 90 % as 597
of the planned 662 colonoscopies were performed. The
study concludes that colonoscopic surveillance with high
patient compliance to the program is effective in prevent-
ing CRC when using a decentralized method for colono-
scopy surveillance with the guidance of a cancer
prevention clinic.
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Introduction
A family history of colorectal cancer (CRC) is a well-
known risk factor for developing cancer [1–4]. CRC risk
increases according to the number of relatives diagnosed
with CRC and the number of relatives diagnosed with early
age CRC. Consequently, families with a strong dominant
pattern of inheritance, indicating a hereditary colorectal
cancer (HCRC) syndrome, have a higher risk compared to
families with a more moderate clustering (i.e., familial
colorectal cancer, FCRC).
In families with known HCRC syndromes, such as Lynch
syndrome, colonoscopic surveillance may reduce colorectal
A part of the study has been presented as a poster at the European
Society for Coloproctology (ESCP) Barcelona, Spain, 24–26 Sept
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cancer incidence and mortality [5]. Hence, surveillance in
Lynch syndrome is well established and international
guidelines recommend annual or biennial colonoscopies
from the age of 20–25 [3, 6, 7]. For FCRC, however, the
evidence of the benefits of colonoscopic surveillance is more
limited [8–10]. As a consequence, international guidelines
and practices for surveillance in FCRC are very divergent
regarding when surveillance should start and the length of
the examination intervals. The recommendations for starting
surveillance ranges between 25 and 50 years old with
intervals of 3–5 years [6, 7].
In the Northern Sweden Health Care Region, all indi-
viduals recommended for HCRC and FCRC surveillance
since 1995 are prospectively recorded in a quality register
at the Cancer Prevention Clinic at the University Hospital
in Umea˚, Sweden.
This study evaluates the CRC preventive effect for the
individuals in the registry in order to optimize future
strategies for surveillance. The evaluation includes ana-
lyzing the colonoscopic findings and describing patient




The study subjects were prospectively recorded in the
colonoscopic surveillance registry at the Cancer Prevention
Clinic at Umea˚ University Hospital from 1995 to 1
September 2012. Colonoscopic surveillance was offered to
individuals with an estimated lifetime risk of colorectal
cancer of at least 10 % or in a few cases due to strong
psychological preferences [3, 6, 7]. No individuals with
previous CRC were included in the study.
The surveillance registry comprises data on age, sex,
place of residence, estimated cancer risk, and when appli-
cable microsatellite instability and immunohistochemistry
or genetic screening for hereditary non-polyposis colorec-
tal cancer (HNPCC/Lynch syndrome) genes. In addition
were surveillance intervals and planned and performed
surveillance colonoscopies recorded. The findings of the
colonoscopies were documented including any incomplete
examinations (inadequate bowel cleaning or failure to
reach the caecum).
All cancer risk assessments were centralized to the
Cancer Prevention Clinic at Umea˚ University Hospital,
whereas the performance of the colonoscopies were
decentralized, as these colonoscopies were performed by
physicians and surgeons at local hospitals in northern
Sweden (Fig. 1). There were no formal requirements on the
examiner’s competence (e.g., minimum number of
colonoscopies/year or adenoma detection rates). Before all
planned colonoscopies, the cancer prevention center mailed
a reminder to the local hospital and to the patient. The
readings of the pathology specimens were also decentral-
ized to the local hospitals.
The individuals in the registry were classified into six
groups according to their risk for CRC (Table 1). The
following two risk groups were excluded from the analy-
ses: Individuals with a non-significantly increased cancer
risk who received surveillance on psychological indication
only (Group 1) and known carriers of adenomatous poly-
posis coli (APC) as these individuals have a separate
standard for surveillance, which includes prophylactic
surgery (Group 4).
The current regional surveillance guideline (2009) in
northern Sweden recommends an interval between
colonoscopies of 2 years in Group 3c (HCRC) and 5 years
for all other groups (FCRC) [7]. Before 2009, a three-year
interval was sometimes used for individuals when the
distinction between HCRC and FCRC was difficult to
ascertain.
Statistical analysis
The study’s main outcome measures looked at high-risk
adenomas (HRA) or CRC and compliance with the
surveillance program. HRA was defined as an adenoma
with villous histology, C10 mm diameter, or with high
0 300 km
Fig. 1 Northern Sweden Health Care Region. Median population
1995–2012 898 696 (scb.se). Cancer Prevention Clinic, Umea˚
University Hospital (black circle). Local hospitals (black square,
smaller than the circle)
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grade dysplasia [8]. Findings were analyzed at the first
surveillance and at the follow-up colonoscopies. To vali-
date the findings of cancer, we linked all study subjects to
the Regional Cancer Registry. The individual’s place of
location was defined as a sparsely populated according to
definitions by Swedish Association of Local Authorities
and Regions [11].
To evaluate the effectiveness of the surveillance pro-
gram in preventing cancer, we estimated the expected
numbers of colorectal cancers for the study population
without surveillance. These estimations were based on age-
specific CRC incidence rates for the general population in
Sweden [12] and on the relative risk for patients with
HCRC or FCRC as proposed by Dowe-Edwin [8]. Dowe-
Edwin’s data on relative risk are specific to age and risk
group (family history) and are categorized as lowest, best,
or highest estimate. To increase the reliability, we used two
methods—A and B—to estimate the expected numbers of
CRC in the study population.
Using method A, we calculated the annual expected
numbers of CRC in the study population using age-specific
general population rates multiplied with the relative risk
according to age and family history, and then summed for
the entire study period.
Using method B, an already developed model for cancer
incidence simulation (Person Years, PYRS), estimated age,
sex, and calendar year adjusted CRC incidence. PYRS has
been described in detail elsewhere[13]. To compare
observed versus expected cases of CRC, two tailed stan-
dard incidence ratios (SIR) with 95 % confidence intervals
were calculated according to Byar’s formula.
To compare baseline characteristics between the risk
groups, we performed independent T test or the Chi square
test. To analyze differences in findings at colonoscopy
between patients with different sex, age, and risk, we used
binary logistic regression. The regression models were
adjusted, when appropriate, for sex, age and risk. The
analysis was performed in IBM Statistics SPSS for Mac,
version 20 and 22.
The Regional Ethical Review Board in Umea˚ approved
the study and all study subjects gave their informed consent
to be included in the registry.
Results
During the study period, 278 individuals from 118 different
families were recorded in the registry and scheduled for
691 colonoscopies. All study subjects in Group 1 (very low
risk, n = 10) and Group 4c (APC carriers, n = 7) were
excluded from analysis. The remaining 261 study subjects
overall compliance to the surveillance program was 90 %
(597 of their planned 662 colonoscopies were performed).
There were no significant differences in mean age
(p = 0.23), sex (p = 0.18), risk group (p = 0.056) or place
of location (p = 0.59) between non-compliant and com-
pliant individuals. Overall was 36.4 % of the study popu-
lation living in sparsely populated areas.
Of the performed examinations, 10 % (60/597) were not
complete. Due to inadequate bowel cleaning 17 % (10/60)
or failure to reach the caecum 83 % (50/60). Out of the
incomplete examinations, 47 % (28/60) were later
Table 1 Classification of family history for estimation of life time risk for colorectal cancer (CRC), regional guidelines for start of surveillance
and intervals
Risk group Family history (FDR = first degree relative) Start of surveillance Intervals between
colonoscopies
Familial colorectal cancer ( FCRC)
la At least two relativesb with CRC diagnosed
over age 70
Individually Individually
2 (2FDR) 2 FDR with CRC diagnosed under age 70 5–10 years before the age of first
diagnosed CRC case in the family
5 years
3a (3FDR) 3 FDR with CRC diagnosed under age 70 5–10 years before the age of first
diagnosed CRC case in the family
5 years
3b (Amsterdam-) Fulfilling all Amsterdam criteria except one 5–10 years before the age of first
diagnosed CRC case in the family
5 years
Hereditary colorectal cancer (HCRC)
3c Fulfilling Amsterdam criteria or MSI positive
or MMR mutation regardless of family
history
Age 25 2 years
4a (FAPc) Known APC carrier Age 12 2 years
a Excluded from analysis
b First or second degree relatives
c Familial adenomatous polyposis (FAP) or Attenuated familial adenomatous polyposis (AFAP)
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completed with a new colonoscopy or diagnostic imaging.
There was no difference in the proportion of complete
examinations between densely and sparsely populated
areas (p = 0.44).
First surveillance colonoscopies
The mean age for the first planned colonoscopy was
53 years, and more women (61 % 159/261) than men were
registered. HCRC patients (Group 3c) were significantly
younger compared to all FCRC patients (Groups 2, 3a, and
3b together) (50.7 vs. 55.4 years, p = 0.001) (Table 2).
There was no significant difference in mean age between
men and women (p = 0.20).
For the first surveillance colonoscopies, 80.6 % (191/237)
were normal, 5.9 % (14/237) showed a HRA, and no cancers
were found (Table 3). The first examination revealed more
men than women (7.6 % (11/145) vs. 3.3 % (3/92),
p = 0.008) with HRA. The probability of finding a HRA on
the initial colonoscopy also increasedwith age (p\ 0.0001),
but was not associated to group (p = 0.79). Even if all FCRC
groups (2, 3a, 3b) were considered as one group and com-
pared to HCRC (3c), there was no significant difference in
proportion of HRA (7.7 vs. 4.5 % p = 0.54). The youngest
FCRC (Group 2, 3a, and 3b) patient with a HRAon the initial
examination was 41 years old, whereas the youngest HCRC
patient with HRA was 34 years old.
Follow-up time
The total follow-up time for the study subject’s risk of
developing CRC was 1256 person years (time from first
colonoscopy until last notification in the Local Cancer
Registry, 1 September 2012). Individuals in Group 3c
(HCRC) were followed for 796 person years For the risk of
developing adenomas, the follow-up time was 760 person
years, based on the 149 patients who were examined at
least twice. The median time between their first and last
colonoscopy was 5.1 years. The consistency between the
recommended surveillance intervals by the genetic coun-
selor and the regional guidelines for surveillance were over
80 % for all groups (Supplementary Table A).
Follow-up surveillance colonoscopies
On the follow-up colonoscopies, one cancer and 12 high-
risk adenomas were found and 281 of the 356 (78.9 %)
examinations were normal (Table 4). All 13 patients with
HRA or CRC had their follow-up colonoscopies within
4 months from their planned date according to their
surveillance interval. However, in 3 cases, the previous
colonoscopy was not complete.
The risk of finding a cancer or a HRA on follow-up was
increased with the patient’s age (p\0.0001) but was not
associated to risk group (p = 0.94) or sex (p = 0.89). The
youngest HCRC patient with HRA was 40 years old and the
youngest FCRC patient was 50 years old. Although no indi-
vidual in Group 2 (2 FDR with CRC) developed adenomas, it
was not a statistically significant result.When all FCRCgroups
(2, 3a, and3b)were compared as onegroup toHCRC(3c), there
was still no significant difference in proportion ofHRAorCRC
(3.1 vs. 3.4 %, p = 0.67). The patient’s follow-up findings at
colonoscopy were compared to the initial findings (Table 5).
Adenomas (simple, multiple, high risk, or cancer) at the initial
examination and increased age at follow-up were associated
with adenomas at the follow-up (p = 0.007 and p = 0.003,
respectively). However, among the seven FCRC patients
[60 years old and without adenomas at the initial colono-
scopy, none had developed adenomas at the follow-up.
No CRC associated deaths were reported, but seven
individuals died of other causes during the study period.
Two patients in group 3c who had very large HRA on their
first colonoscopy and the patient with CRC needed surgical
intervention.
Table 2 Baseline characteristics for individuals in the registry for surveillance of familial (FCRC) or hereditary colorectal cancer (HCRC) in
northern Sweden
Risk group Families n (%) Females n (%) Males n (%) Individuals n (%) Mean age for planned first
colonoscopy (range)
2 (2 FDR) 21 (19) 20 (74) 7 (26) 27 (100) 52.3 (32–72)
3a (3 FDR) 29 (27) 34 (55) 28 (45) 62 (100) 54.6 (34–75)
3b (Amsterdam-) 11 (10) 16 (55) 13 (45) 29 (100) 60.1 (39–79)
3c (HCRC)a 47 (44) 89 (63) 52 (37) 141 (100) 50.7b (24–78)
Total 108 (100) 159 (61) 100 (39) 259c (100) 52.8 (24–79)
Individuals in Groups 1 and 4 are not included
a Composition of HCRC group: 51.7 % MMR mutation carriers, 19.6 % Amsterdam positive but not mutation carriers, 28.7 % Amsterdam
positive but not tested for MMR mutations
b HCRC patients (Group 3c) were significantly younger compared to all FCRC patients (Groups 2, 3a and 3b altogether) (p\ 0.0001)
c Two study subjects excluded due to missing data on group or age
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The patient who developed CRC was a 70 year-old
patient in Group 3c (HCRC) who fulfilled the Amsterdam
criteria but was not tested for microsatellite instability or
HNPCC genes. The cancer was diagnosed after diagnostic
and treatment difficulties of a suspected earlier found HRA.
Expected numbers of CRC
Without surveillance, the best estimate for expected num-
bers of CRC in the study population would range from 9.5
to 10.5 cases during the study period, depending on the
statistical method used (Method A or B). The standardized
incidence ratios (SIR), observed versus expected cases of
CRC, based on the best estimates are between 0.10 (CI
95 % 0.0012–0.5299) and 0.11 (CI 95 % 0.0014–0.5857)
(Table 6). This indicates a possible significant reduction in
CRC due to surveillance.
If the studied population would have had the same risk
for CRC as the general population in Sweden, the expected
numbers of CRC are approximately 0.8.
Table 3 Most advanced finding at first surveillance colonoscopy
Risk group Normal Metaplastic polyp Simple adenoma Multiple adenoma High risk adenoma Cancer Total
2 (2 FDR) 19 (79.2) 2 (8.3) 1 (4.2) 1 (4.2) 1 (4.2) 0 24 (100)
3a (3 FDR) 40 (78.4) 1 (2) 5 (9.8) 0 5 (9.8) 0 51 (100)
3b (Amsterdam-) 22 (75.9) 2 (6.9) 1 (3.4) 2 (6.9) 2 (6.9) 0 29 (100)
3c (HCRC) 110 (82.7) 6 (4.5) 10 (7.5) 1 (0.8) 6 (4.5) 0 133 (100)
Total 191 (80.6) 11 (4.6) 17 (7.2) 4 (1.7) 14 (5.9) 0 237a (100)
Values are number (%) of patients
a 23 patients were never examined and one patient was excluded due to missing data on finding
Table 4 Most advanced finding at all follow up colonoscopies
Risk group Normal Metaplastic polyp Simple adenoma Multiple adenoma High risk adenoma Cancer Total
2 (2 FDR) 12 (92.3) 1 (7.7) 0 0 0 0 13 (100)
3a (3 FDR) 36 (81.8) 3 (6.8) 4 (9.1) 0 1 (2.3) 0 44 (100)
3b (Amsterdam-) 28 (73.7) 4 (10.5) 3 (7.9) 1 (2.6) 2 (5.3) 0 38 (100)
3c (HCRC) 205 (78.5) 15 (5.7) 28 (10.7) 3 (1.1) 9 (3.4) 1 (0.4) 261 (100)
Total 281 (78.9) 23 (6.5) 35 (9.8) 4 (1.1) 12 (3.4) 1 (0.3) 356a (100)
Values are number (%) of examinations
a Three examinations were excluded due to missing data on finding
Table 5 Relationship between patients’ most advanced finding on first colonoscopy and on any follow-up colonoscopy










Normal (n = 116) 76 (65.5) 13 (11.2) 16 (13.8) 2 (17.2) 8 (6.9) 1 (0.86)
Metaplastic polyp (n = 7) 5 (71.4) 1 (14.3) 1 (14.3) 0 0 0
Simple adenoma (n = 8) 4 (50) 1 (12.5) 3 (37.5) 0 0 0
Multiple adenoma (n = 3) 1 (33.3) 0 0 1 (33.3) 1 (33.3) 0
High risk Adenoma (n = 9) 2 (22.2) 0 5 (55.6) 1 (11.1) 1 (11.1) 0
Total (n = 143a) 88 (61.5) 15 (10.5) 25 (17.5) 4 (2.8) 10 (7.0)b 1 (0.7)
Values are number of patients (%)
a Three patients were excluded due to missing data
b One patient had high risk adenomas on two follow-up colonoscopies, another patient had high risk adenoma on one follow u on cancer. Hence,
there were 12 follow-up examinations (see Table 4)




This study demonstrated that colonoscopic surveillance
with high patient compliance prevented hereditary and
familial CRC. In our study, only one of the 237 individuals
developed CRC while under surveillance. The decentral-
ized method for colonoscopy surveillance under the guid-
ance of the cancer prevention clinic might have improved
compliance.
Prevention of colorectal cancer
In our study, the proportion of CRC in families with HCRC
was only 0.7 % (1/134), or an incidence rate of one case in
796 years of follow-up. This incidence rate is comparable
to a population without increased familial risk for
CRC[12]. Three previous controlled trials of colonoscopic
surveillance in Lynch syndrome, all comparing the out-
come between unscreened and screened patients, report a
proportion of CRC ranging from 3.5 to 10.9 % in the
screened group [4, 14, 15]. These higher numbers can
partly be explained by a longer surveillance interval in one
of the earlier trials[4], but two recent studies use the same
intervals as in our program (i.e., 2 years) [14, 15]. How-
ever, comparisons between controlled and prospective
studies should be made with caution, as many of these
studies use different definitions of HCRC and Lynch
syndrome.
Only a few prospective studies present results of
surveillance of both HCRC and FCRC.
A large study by Dowe-Edwin et al. (2005) includes
patients both with HCRC (surveillance with 2-year inter-
vals) and FCRC (surveillance with 5-year intervals) and
reports a CRC incidence in the same order of magnitude as
in our study, 1/1200 person years versus 11/11,000 person
years [8]. Their recommended start of surveillance was
25 years for both HCRC and FCRC, with a lower mean
age at first examination than in our study (41 vs. 53 years).
However, the earlier start of surveillance of the FCRC
group does not seem to have increased the efficiency in
preventing CRC.
A recent prospective multicenter study by Mesher et al.
reports an incidence of CRC of 1.14 per 1000 person-years,
but the surveillance strategy varied at the different partic-
ipating centers (1–5 year intervals) [16].
In summary, the CRC preventive effect in our study was
equal to or better than the effect shown in other studies.
An important factor for preventing CRC is the patient’s
compliance to the surveillance program. In our study, the
patient compliance was very high (90 %), compared to
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programs in the general population [17, 18]. We have not
found information on compliance in previous reports on
surveillance of FCRC or HCRC. Participation rates for
cancer screening are assumed to be higher in rural areas
and among females [18, 19]. In our study there was no
difference in compliance between sparsely and densely
populated areas according to Swedish definitions. However
compared with most other countries, almost the entire
northern Sweden could be considered a sparsely populated
area. Consequently, it is difficult to determine if the high
compliance in our study was due to the decentralized
organization of the surveillance, or by an overall rural
setting and a predominance of female study subjects. This
may affect the possibility to reproduce high compliance
with decentralized surveillance in another setting.
Another factor affecting CRC prevention might be the
quality of the colonoscopies. Our reported rate of 10 %
incomplete colonoscopies is high compared to international
quality targets for CRC screening [6, 20]. The reason may
be the lack of nationwide quality assurance guidelines for
colonoscopies in Sweden. The slightly lower quality of the
colonoscopies in our study has nevertheless not resulted in
a low CRC preventive effect.
However, without any kind of modeling is it hard to
determine how important compliance and quality of
colonoscopies are for CRC prevention compared to other
factors as start of surveillance and intervals.
Start of surveillance and intervals
An accelerated adenoma-carcinoma pathway is often used to
explain the increased risk for patients with a family history of
CRC [21]. Theoretically, the speed of the pathway decides at
what age surveillance should begin and how often a patient
should be re-examined to detect new pre-malignant adeno-
mas. Hence, evaluation of the findings at the initial colono-
scopy may optimize the timing for the start of surveillance,
whereas the length of intervals is best determined by the
findings gathered from follow-up examinations.
In this study, more men than women had HRA at the
initial colonoscopy, whereas there were no gender differ-
ences at the follow-up examination. The difference at the
first examination may have been caused by an increased
background risk because men typically have more HRA
and CRC than women [22, 23].
At the first examination, individuals with FCRC had a
mean age of 55.4 years and 7.7 % had HRA. In a popu-
lation without increased risk for CRC, the rate of HRA has
been reported to be 3.8 % for all patients \65 years or
5.7 % for patients 40–49 years old [23, 24]. The higher
proportion of HRAs in our population is expected because
of their overall increased risk for CRC, but it is not clear at
what age HRAs start to develop in individuals with FCRC.
Our findings are consistent with other studies of FCRC,
reporting a sharp increase in the proportion of HRA on the
initial examinations around age 50 [8]. Consequently,
starting surveillance for FCRC between 40 and 50 years or
5–10 years before the first case of CRC in the family seems
reasonable. However, in this study, albeit with low sub-
group numbers, patients over 60 years old with FCRC and
no adenomas on the initial colonoscopy seem to have a
very low risk of developing any adenomas by the follow-
up. If confirmed in other larger studies, a single colono-
scopy could be a future strategy for FCRC surveillance [3].
On the follow-up colonoscopies, there was no difference
between HCRC and FCRC in the rate of HRA and CRC
(3.1 vs. 3.4 %). Earlier studies conclude patients with
HCRC have an accelerated adenoma-carcinoma pathway
and new HRA can develop from a clean colon in a few
years [4, 8, 21, 25]. Our findings suggests that colonoscopic
surveillance with a two-year interval in HCRC and a five-
year interval in FCRC equalized the risk for development
for HRA between HCRC and FCRC and reduced the risk of
CRC to that of the general population (i.e., average risk).
However, if all CRC is to be prevented, a shorter interval in
HCRC might be necessary, a recommendation found in the
British guidelines for Lynch syndrome [3].
More frequent colonoscopies with detection and
polypectomy of simple adenomas before progression may
prevent development of HRA. To prevent all HRA would
require an intensive surveillance regimen resulting in high
health care costs and possible discomfort for the patients.
But what is the optimal HRA detection rate in a surveillance
program? From a health economic perspective, it might be
sufficient to detect any HRA early enough to allow endo-
scopic polypectomi instead of surgery. In our study, 7.6 %
(2/26) of patients with HRA required surgical intervention, a
low percentage compared to other studies [26, 27].
Limitations
The major limitation of this study is the lack of a control
group, which necessitates an estimate of the expected cases
of CRC without surveillance. However, with the knowl-
edge we have today, it would be considered ethically
problematic to randomize patients with an increased risk of
CRC to non-surveillance. Hence, the best available option
to optimize surveillance in the future is prospective studies
that focus on different on-going surveillance programs.
Another weakness is the limited number of patients in the
different FCRC risk groups. Valid subgroup analysis
becomes difficult, especially for low risk patients where the
beneficial effects of surveillance might be low.
The median follow-up time of approximately 5 years
may also be too short; many patients may have not been
followed long enough to develop a CRC.
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Strengths of the study
The main strength of the study is the quality of the follow-up
using Sweden’s unique personal identification number and
the link of all patients to the Local Cancer Registry. The
Cancer Registry started in 1958, and its validity on cancer
data in Sweden is over 95 %, which makes the possibility of
further unreported cases of CRC low [28]. The cancer history
in the families are validated through the Cancer Registry and
through saved medical records, providing robust informa-
tion of the exact numbers and age at diagnosis of cancer
among family members. Our study is also one of the few
studies to report compliance with surveillance [29].
Conclusions
Our study provides a reasonably safe strategy for surveillance
of FCRC and HCRC with high patient compliance in a
sparsely populated area by using decentralized colonoscopies.
However, health economic analyses andmodeling are needed
to find the most cost effective way to prevent cancer devel-
opment in individuals with a family history of CRC. These
future studies of surveillance programs should include patient
compliance as an important factor and not only focus on start
of surveillance and the lengths of the intervals.
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